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The anthracycline anticancer drug doxorubicin is an effective and frequently used chemotherapeutic agent for various malig-
nancies but it causes acute ventricular dysfunction, and also induces cardiomyopathy and heart failure. One of the mechanisms of 
cardiotoxicity of doxorubicin is oxidative stress, which stimulates myocardial remodeling. Matrix metalloproteinases MMP2 and 
MMP9 play a key role in this process. Despite extensive research, the expression and activity of these enzymes in the doxorubicin-
damaged heart and the effect of antioxidants on these indicators have not been sufficiently studied. The aim of this work was to 
study the possible cardioprotective effect of the antioxidant drugs corvitin and alpha-ketoglutarate in rats with doxorubicin-
induced cardiomyopathy. Cardiomyopathy in rats was induced by intraperitoneal administration of doxorubicin at the dose of 
2.5 mg/kg body weight weekly for 28 days. Animals were divided into four groups: group 1 (control) received saline injections 
(2.5 mL/kg); group 2 – injections of doxorubicin, 3 – corvitin (5 mg/kg) 60 minutes before doxorubicin administration, 4 – dox-
orubicin and 1% solution of alpha-ketoglutarate in drinking water ad libitum. Heart weight and shape indexes, the ratio of muscle 
to connective tissues, and heart histology were examined 7 days after the end of drug administration. Activity of MMP2 and 
MMP9, their intracellular distribution in myocardial tissues were evaluated by gelatin-zymography and immunohistochemistry. It 
was found that doxorubicin cardiomyopathy in rats was accompanied by a decrease in heart weight index, adaptive change of heart 
shape from ellipsoid to globular, increase of connective tissue content. Administration of doxorubicin results in profound lesion of the 
cardiomyocytes of the atria and ventricle, manifested by excessive cytoplasmic expression of MMP2 and MMP9 and an increase their 
activity in the heart. Antioxidants corvitin and alpha-ketoglutarate have insufficient regenerative effect on mass and shape indexes of 
heart however, exhibit potent cardioprotective effect by regulation of expression and activity of MMP2 and MMP9.  
Keywords: gelatinases A and B; heart diseases; anthracycline antibiotic; antioxidants.  
Introduction  
 
Doxorubicin is one of the most effective anticancer drugs of the 
group of anthracycline antibiotics used to treat various types of cancers. 
However, its therapeutic utility is severely limited by its associated car-
diotoxicity. Despite the enormous amount of research in this area, the 
exact molecular mechanisms underlying the toxic effects of doxorubicin 
on the heart are still an area that warrants further investigation. Analysis 
of the literature data suggests that the mechanisms of doxorubicin’s 
cardiotoxicity are multifactorial (Renu et al., 2018; Wenningmann et al., 
2019) and include the impairment of mitochondrial energetics, increase 
of reactive oxygen species (ROS) leading to oxidative stress, cell necro-
sis and induction of pro-apoptotic signaling pathways (Chaudhari et al., 
2017; Pecoraro et al., 2017; Delehanty et al., 2018).  
The most common manifestations of the cardiotoxicity of doxoru-
bicin are cardiac dysfunction and dilated cardiomyopathy. Moreover, 
the degree of damage to the heart depends on the dose and duration of 
doxorubicin administration (Chatterjee et al., 2010; Loncar-Turukalo 
et al., 2015; Mancilla et al., 2019). An application of this drug was also 
found to influence sensitivity of the heart to ischemic injury. A recent 
study demonstrated that administration of doxorubicin upon induction 
of ischemia significantly increased the size of the infarction (Gharanei 
et al., 2013), but the exact mechanisms of these changes remains unclear. 
Doxorubicin-induced heart failure develops over a prolonged time 
period and is associated with myocardial remodeling, which also in-
volves changes in some structural proteins of the extracellular matrix. 
The matrix metalloproteinases (MMPs) play an important role in remo-
deling of the extracellular matrix. A special place for remodeling of the 
myocardium belongs to gelatinase A (MMP2) and gelatinase B or 
MMP9 (Polegato et al., 2015; Antonov et al., 2018). Due to their ability 
to hydrolyze collagen IV, which is the main component of the basal 
membranes, these MMP are involved in the development of numerous 
metabolic diseases, in processes of invasion, metastasis, vascularization/ 
angiogenesis and tissue remodeling (Hahn et al., 2014). That is why it is 
absolutely justified to study these enzymes in the heart of rats with dox-
orubicin-induced cardiomyopathy.  
A number of potential cardioprotective drugs have been explored 
including anti-oxidants, free radical scavengers, renin-angiotensin-sys-
tem antagonists, cardioselective beta-blockers and statins (Shaker et al., 
2018; Wenningmann et al., 2019). Despite promising animal studies, 
clinical trials have yielded conflicting results (Razavi-Azarkhiavi et al., 
2016; Cappetta et al., 2017). Recently, close attention has been paid to 
the bioflavonoid quercetin, which possesses various biological properties 
including anti-oxidative, anti-inflammatory, anti-coagulation, and anti-
radical activities. Quercetin has certain preventive actions in the treat-
ment of cardiovascular diseases (Jin et al., 2012; Patel et al., 2018), its 
applications before ischemia or during reperfusion protect the myocar-
dium from ischemia/reperfusion injury (Bartekova et al., 2015). How-
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ever, the effect of this drug on the heart remodeling has hardly been 
studied. It should be noted that poor intestinal solubility and absorption, 
as well as rapid neutralization after oral administration – the “flavonoid 
paradox” – limit the bioavailability of this flavonoid (Gonzales et al., 
2017). Currently, corvitin, which is a water-soluble form of quercetin for 
intravenous injections, is used as a drug with a pronounced anti-ischemic, 
anti-stroke, and anti-infarction activity. Corvitin has a high bioavailability 
with a sufficiently low level of its toxicity (Gonzales et al., 2017).  
Another drug that can prevent the development of doxorubicin-in-
duced cardiomyopathy is alpha-ketoglutarate. This central metabolite of 
the Krebs cycle is involved in multiple metabolic cellular signaling 
pathways. It functions as an energy source, a precursor in the amino 
acid biosynthesis, a signaling molecule, as well as a regulator of epige-
netic processes (Sinton et al., 2017). It regulates the activity of prolyl-4 
hydroxylase, which controls the biosynthesis of collagen, a component 
of connective tissue, and influences the function of the hypoxia-inducible 
factor, an important transcription factor in development and progression 
of neoplasia (MacKenzie et al., 2017). The metabolic and extra-metabo-
lic functions of alpha-ketoglutarate in the organism open many different 
fields for therapeutic interventions. The regulatory role of alpha-keto-
glutarate and its structural analogues in carcinogenesis and possibilities 
of using it as an anticancer agent are now being discussed (Sultana et al., 
2016; Zdzisinska et al., 2016). Despite significant advances in the study 
of the therapeutic effects of alpha-ketoglutarate, its influence on the pro-
cesses of heart regeneration is not well understood.  
The aim of this work was to study possible cardioprotective effects 
of corvitin and alpha-ketoglutarate in rats with doxorubicin-induced 
cardiomyopathy.  
 
Materials and methods  
 
Animals. The care and use of animals was conducted in compliance 
with the principles outlined in the current Guide to the Care and Use of 
Experimental Animals and in accordance with the ethical standards es-
tablished by the Law of Ukraine No 3447-IV, dated 21.02.2006 “On the 
Protection of Animals from Cruelty”. The protocol of the experiments 
on the animals was approved by the Local Ethics Review Committee 
on Animal Experiments in Dnipropetrovsk Medical Academy (Dnipro, 
Ukraine). Wistar male rats weighing 210 ± 5 g were exposed to stan-
dard conditions, such as reverse 12 h light-dark cycle and provided with 
laboratory nutrition and water ad libitum.  
Reagents. Bovine serum albumin (BSA), gelatin (Sigma, США); 
doxorubicin-KMP, thiopental-KMP (Public Joint Stock Company “Ky-
ivmedpreparat”, Ukraine); corvitin (Borshchahivskiy Chemical-phar-
maceutical Plant, Ukraine); alpha-ketoglutarate (SGPlus, Sweden); 3,3-
diaminobenzidine tetrahydrochloride (visualization system LabVisison 
Quanto, TermoScientific); standard kits for determination of aspartate 
aminotransferase, lactate dehydrogenase, creatine kinase MB (Elitech 
diagnostics Seppim S.A.S., France); acrylamide/bis-acrylamide, electro-
phoresis protein molecular weight standards (Bio-Rad Lab, USA); 
MMP2/9, rabbit polyclonal antibodies to MMP2/9 (Sigma, USA), goat 
antibodies to rabbit IgG conjugated with horseradish peroxidase (HRP-
conjugate, Proteintech Group, USA).  
Experimental protocol. Doxorubicin cardiomyopathy (DCMP) in 
rats was induced by intraperitoneal injections of the anthracycline anti-
biotic doxorubicin weekly during 28 days in dose 2.5 mg/kg of weight 
(Kapelko, 1990). The animals were randomly divided into four groups, 
ten rats in each group. The 1st group (control) received saline injections 
(2.5 mL/kg); the 2nd group of animals underwent doxorubicin cardi-
omyopathy (DCMP), the 3rd group of rats received corvitin (5 mg/kg) 
60 minutes before doxorubicin injection. The animals of the 4th group 
received DCMP and 1% solution of alpha-ketoglutarate (AKG) in drin-
king water (0.5% Са-AKG + 0.5% Na-AKG) ad libitum. The rats con-
sumed 40–43 mL of water per 1 kg of weight. By the end of experi-
ment, euthanasia of rats was performed using sodium thiopental 
(60 μg/kg), the hearts and blood plasma were taken out and used for the 
subsequent research.  
Cardiac morphometry. The extracted hearts were dried on paper 
filters, fixed in 10% neutral formalin 10 min and then their weight and 
morphometric characteristics were determined (Nazarova et al., 2014). 
The morphometry of histological preparations of the ventricles and atria 
were performed with a point technique using a special transparent ste-
reometric grid. The microscopic field of view was covered with a grid 
on which the points are located at the same distance from each other. 
The percentage of connective tissue to muscle was determined in ten 
fields of view by the ratio of the number of points that were overlaid on 
one or another type of tissue (Avtandilov, 2002).  
The heart weight index was calculated as the ratio of the heart weight 
to the body weight of the experimental rats by the following formula: 
HWI = (m/M) × 100,  
where HWI – heart weight index (%), m – heart weight (g) and M – 
body weight (g) of experimental animals.  
The heart shape index was determined as follows:  
HSI = (b/l)×100,  
where HSI – heart shape index (%), b – width of heart (cm), l – length 
(cm) of heart. The shape of the heart at this index was evaluated as 
following: ˂  65% – conic, 65–75% – ellipsoidal, ˃  75% – globular.  
Biochemical analysis. Plasma of experimental animals was used for 
biochemical analysis, where activity of aspartate aminotransferase (AST), 
lactate dehydrogenase (LDH) and MB-form of creatine kinase (CK-MB) 
was determined according to the instructions of commercial test-systems.  
Histopathology and immunohistochemistry. The left part of the rat 
hearts fixed in 10% formalin was buffered in PBS (pH 7.4) for 24 hours 
at room temperature, dehydrated in increasing concentrations of isopro-
panol and embedded in paraffin. At least four 5 μm thick slices of the 
left atrium and ventricle were obtained from each specimen for histo-
logical study of the structural changes in the myocardium. All sections 
were evaluated using  light microscopy (Zeiss Primo Star microscope) 
at a magnification of ×400.  
The expression of MMP2 and MMP9 was evaluated by immuno-
histochemical analysis, using an indirect two-step method. The sections 
were deparaffinized with xylene, rehydrated with graded ethanol and 
washed in water. Then the sections were boiled in a microwave for 
15 min for antigen retrieval, after which they were treated with 3% hyd-
rogen peroxide for 15 min at room temperature to block endogenous 
peroxidase. The sites of nonspecific antibody binding were blocked by 
BSA-containing solution, after which the tissue sections were incubated 
with rabbit polyclonal antibodies (1:300) against MMP2 and MMP9 for 
60 min at room temperature. Then, the sections were washed three 
times with phosphate-buffered saline (PBS) and incubated for 60 min 
with the HRP-conjugate at room temperature. The slices were washed 
by PBS again and exposed with 3,3-diaminobenzidine tetrachloride for 
5 min at ambient temperature, washed in distilled water, post-stained 
with Mayer’s hematoxylin. To quantify immunohistochemical expres-
sion, 7 to 10 fields in each slide (at a magnification of 400 times) were 
randomly chosen and colour reaction was evaluated (brown cytoplas-
mic staining). The results are presented as four different levels: 0 – ne-
gative, 1 – weak, 2 – moderate, and 3 – strong, reaction.  
Fractionation of the soluble cardiac proteins. The fractions of soluble 
cardiac proteins were obtained by homogenization of the heart pieces in 
0.025 М tris-НСl buffer pH 7.2 in the ratio 1:4 (g/mL), following centri-
fugation at 2860 g during 5 min at 4 ºС. The supernatants were sampled 
for further experiments. Protein concentrations in fractions of soluble 
cardiac proteins were determined by the Bradford (1976) method.  
Gelatin-zymography. Activities of MMP2 and MMP9 were deter-
mined by the method of direct gelatin-zymography after vertical electro-
phoresis of the fractions of soluble cardiac proteins in 7.5% polyacryl-
amide gel containing 0.1% SDS and 1% gelatin. After electrophoresis, 
the gels washed twice for 20 min each with 50 mmol/L Tris-HCl 
(pH 7,4), containing 2.5% Triton X-100, and then incubated 24 hours at 
37 °C in a substrate buffer containing 50 mmol/L Tris-HCl, 10 mmol/L 
CaCl2 and 1.25% Triton X-100 (pH 7.4). After incubation, the gels 
were stained with 1% Coomassie Brilliant Blue G-250 and then destai-
ned using the mix of 40% methanol and 10% acetic acid. The MMP 
were manifested as transparent bands against a dark blue background. 
In the following step, zymograms were converted into digital format 
and activity of MMPs calculated with the program Videodensitometer 
Sorbfil 2.0. The activities of MMP2 and MMP9 were evaluated in arbi-
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trary units (AU) relative to their level in the standard sample, where the 
activity was taken as 1 AU. As a standard, we used a pool of cardiac 
fractions of the control group, which was obtained by mixing of the 
equal volumes of the fraction of soluble cardiac proteins in the control 
group (Shevcova et al., 2013). The aliquots of the standard were stored 
at –80 °С. Specific activity of the studied enzymes in the hearts were 
calculated per 1 mg of protein.  
Statistical analysis. All data are presented as the means (x) and 
standard error (SE). Statistical analysis was performed using analysis of 
variance (one-way ANOVA) followed by the Tukey’s multiple com-
parisons post hoc test. A value of P ˂ 0.05 was considered as statistical-
ly significant.  
 
Results  
 
Physiological and biochemical parameters in plasma of the expe-
rimental rats. It was found that behavioural reactions of rats were sup-
pressed after the doxorubicin injections due to deterioration of their 
physical and emotional states. Mortality in the experimental groups of 
animals was 15.6%. The body weight of control group  rats increased 
from 210.3 ± 6.3 g at the beginning of the experiment to 229.3 ± 11.8 g 
at the time of its completion. The weight of DCMP-rats had a tendency 
to decrease, it was only 93.8% by the end of the experiment compared 
with the start. A decrease of body weight by 16.2% observed in rats on 
the background of corvitin administration. The weight of the animals 
which consumed alpha-ketoglutarate with drinking water remained al-
most unchanged (Fig. 1).  
 Fig. 1. The body weight (g) of rats during the experiment:  
1 – control group, 2 – DCMP – group, 3 – DCMP + corvitin,  
4 – DCMP + alpha-ketoglutarate; DCMP – doxorubicin-induced  
cardiomyopathy; error bars represent means x ± SE; statistical analysis  
was done by an one-way ANOVA with Tukey post hoc test  
Biochemical studies were conducted to confirm doxorubicin-indu-
ced myocardial damage at the end of the experiment. The activities of 
aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and 
MB-form of creatine kinase (CK-MB) were evaluated in the blood 
plasma of all animal groups (Table 1).  
Table 1  
The activity (IU/L) of aspartate aminotransferase (AST), lactate dehydro-
genase (LDH) and MB-form of creatine kinase (CK-MB) in blood plas-
ma of experimental rats (x ± SE, duration of experiment – 28 days)  
Parameter 1st group (control, n = 8) 
2nd group 
(DCMP, n = 6) 
3rd group 
(DCMP + 
corvitin, n = 7) 
4th group 
(DCMP + 
AKG, n = 6) 
AST 145 ± 13a 184 ± 4b 136 ± 9a 158 ± 6ab 
LDH 640 ± 65ab 1168 ± 52c 541 ± 12a 653 ± 30b 
CK-MB 710 ± 99a 749 ± 47a 550 ± 60a 717 ± 60a 
Note: significant difference among groups is indicated by different letters; statistic-
al analysis was done by a one-way ANOVA with Tukey’s multiple comparisons 
post hoc test.  
As follows from the presented data, the activity of all studied en-
zymes increased after the administration of doxorubicin, the most sig-
nificant changes were found for LDH and AST. The activity of AST 
increased 1.3-fold and LDH – 1.8-fold in the DCMP-group relative to 
intact rats. In contrast to AST and LDH, the activity of the CK-MB in 
2nd group of animals changed slightly.  
It was found that the preventive use of corvitin or alpha-keto-
glutarate had almost the same effect on the activity of the enzymes in 
rats with DCMP, both drugs significantly reduced the activity of AST 
and LDH in comparison with DCMP-group. It was also found that both 
the separate administration of doxorubicin and the use of this drug in 
combination with alpha-ketoglutarate did not significantly affect the ac-
tivity of CK-MB, but the activity of this enzyme decreased by 26.6% 
after the administration of corvitin compared to the DCMP-group.  
Impact of corvitin and alpha-ketoglutarate on morphological and 
histopathological parameters of the hearts. Morphometric characteris-
tics, the heart weight (HWI) and shape (HSI) indexes were determined 
after pathoanatomical dissection of the animals. It was found that the 
HWI in rats of the DCMP-group decreased compared to the control 
group (0.49 ± 0.05% and 0.62 ± 0.13%, respectively) (Fig. 2a). The use 
of corvitin and alpha-ketoglutarate increased this index, but no complete 
recovery occurred. It should be noted that corvitin has a more pro-
nounced restorative effect than alpha-ketoglutarate.  
a   
b  
c  
Fig. 2. Heart mass (a) and heart shape (b) indexes and the ratio  
of connective tissue to muscle tissue in heart (c) of experimental  
groups of rats: see Fig. 1  
 
Regul. Mech. Biosyst., 2019, 10(4) 375 
  
Fig. 3. Light micrographs of cardiac tissues of rats: control group (a, b), group with doxorubicin-induced cardiomyopathy (c, d), after  
administration of corvitin (e, f) and alpha-ketoglutarate (g, h); stain: Mayer’s hematoxylin; Scale bar: 5 μm; black arrows indicate  
enlarged nuclei of cardiomyocytes with hypertrophy, red triangles – hydropic changes of the cytoplasm of cardiomyocytes  
with the phenomena of karyopicnosis or karyolysis, * – fatty dystrophy  
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Rats of the DCMP-group had a significant increase in HSI com-
pared with intact animals (86.2 ± 4.0% and 72.9 ± 3.4%, respectively), 
indicating a change in shape from ellipsoidal to globular. As can be seen 
from Figure 2b, neither corvitin nor alpha-ketoglutarate prevented these 
changes, although there was a slight tendency to decrease this index 
under the impact of alpha-ketoglutarate.  
Analysis of the histological structure of the myocardium in the ex-
perimental groups allowed us to determine the ratio of connective (CT) 
and muscle (MT) tissues. It was shown that the total content of connec-
tive tissue in the hearts of control group animals was 28% and muscle – 
72% (Fig. 2c). The animals of the DCMP-group exhibited the decrease 
of muscle tissue content to 65% and increase of connective tissue con-
tent to 35%. Calculation of the ratio of muscle tissue to the connective 
tissue in the heart revealed that the connective tissue component ex-
pands in the doxorubicin-injected rats with a corresponding decrease of 
muscle tissue: the ratio CT:MT changes from 0.38 in the control group 
to 0.53 in the DCMP-group. Under impact of corvitin the ratio CT:MT 
was 0.45, and after the application of alpha-ketoglutarate – 0.48, which 
testifies to the cardioprotective effect of the drugs.  
An in-depth analysis of the cellular structures of the left atrium and 
ventricle allowed us to identify some histological changes. Non-damaged 
cardiomyocytes with preserved striation and complete absence of fatty 
dystrophy were present in the heart tissues of the control group (Fig. 3a, b). 
Another pattern was observed in the specimens of heart tissues of the 
DCMP-rats: damaged cardiomyocytes alternated with preserved ones, the 
hypertrophy sites – with the atrophy sites. Damaged cells were characteri-
zed by a combination of hydropic and fatty changes, by disappearance of 
the striation. Islets of cardiomyocytes with signs of karyopycnosis, karyo-
rexis, karyolysis, plasmolysis and the areas of diffuse cardiosclerosis were 
found in the left atrium and ventricle of these rats (Fig. 3c, d).  
Administration of corvitin and alpha-ketoglutarate against the 
background of doxorubicin injections contributes to the improvement of 
myocardial ultrastructure:  most cardiomyocytes remains non-damaged, 
almost complete absence of fatty dystrophy is shown, and the transverse 
striation of the heart muscle remains. Areas of cardiosclerosis in the his-
tological specimens are located only around the vessels, where small 
areas of hypertrophy are found (Fig. 3e–h). However, some cells with 
signs of hydropic dystrophy are saved in case of treatment by alpha-
ketoglutarate.  
Immunohistochemical expression of MMP2/9 in heart tissues of 
rats. Expression of matrix metalloproteinases MMP2 and MMP9 in the 
atria and ventricle of experimental animals were investigated by immu-
nohistochemical analysis (Fig. 4, 5). Careful analysis of immunohisto-
chemical staining of cellular structures revealed certain differences in 
the number and localization of the above mentioned metalloproteinases 
in the studied heart specimens. Negative and weakly positive cytoplas-
mic expression of MMP2 (Fig. 4a) were detected in the ventricular 
tissue of the control group of rats. Areas with moderate MMP2 expression 
(Fig. 4b) presented in the atrium among cardiomyocytes with weak and 
negative expression. As for another proteinase – MMP9 – its expression 
and intracellular localization were similar to MMP2 although the level 
of MMP9 in the atrium was higher than in the ventricle.  
An increase in cytoplasmic expression of MMP2 and MMP9 was 
found in cardiomyocytes of DCMP-group, where rats were administer-
red by doxorubicin for 4 weeks. Particularly intense immunohistoche-
mical staining was observed in places of mosaic accumulation of cardi-
omyocytes with signs of dystrophy (Fig. 4, 5c, d). However, the 
designated enzymes were not detected in the areas of cardiosclerosis in 
the observed specimens. It should be noted a decrease in immunohisto-
chemical staining of MMP2 and MMP9 in cytoplasm of the cells with 
signs of  caryopycnosis and plasmolysis as well as the appearance of 
intranuclear staining instead cytoplasmic (Fig. 6). This result indicates a 
profound damage of the cells, and such histological staining is known as 
dot-like reaction.  
A weak or negative staining of MMP2/9 in the cytoplasm of cardi-
omyocytes was detected in the atrium and ventricle of rats which were 
treated with corvitin on the background of doxorubicin injections. At the 
same time, an increase of the staining intensity in diffusely scattered 
cardiomyocytes with signs of hydropic dystrophy was found in some 
areas of the investigated hearts (Fig. 4, 5e, f).  
The results of investigation of the immunohistochemistry of heart 
tissues in rats of group 4 that received alpha-ketoglutarate were similar 
to those of the corvitin group. As in case of treatment by corvitin, we 
found a poor staining for the presence of MMP2 and MMP9 in the 
cytoplasm of cardiomyocytes. The colour intensity increased to mode-
rate in the cardiomyocytes which were located near the vessels. The areas 
of moderate cytoplasmic staining in cardiomyocytes with signs of hyd-
ropic changing were more common in the ventricle (Fig. 4, 5f, h) than 
in the atrial tissue (Fig. 4, 5e, g). In the ventricle, there was also a strong 
expression of MMP2 and MMP9 in single sites of accumulations of 
cardiomyocytes with fatty dystrophy, but such areas were much smaller 
than in samples of DCMP-group.  
Activity of MMP2 and MMP9 in the heart of experimental rats. 
The activity of matrix metalloproteinases in fractions of soluble cardiac 
proteins was determined by gelatin-zymography in our modification 
with calculation of the relative activity of MMPs in arbitrary units in 1 
mg protein (Table 2).  
Table 2  
Protein concentration and relative activity of MMP2 and MMP9 in fraction 
of soluble cardiac proteins (x ± SE, duration of experiment – 28 days)  
Parameter 
1st group 
(control,  
n = 8) 
2nd group 
(DCMP, 
n = 6) 
3rd group 
(DCMP + 
corvitin, 
n = 7) 
4th group 
(DCMP + 
AKG, 
n = 6) 
Concentration  
of protein, mg/mL 
7.43 ± 
0.91a 
8.72 ±  
0.87ab 
10.02 ± 
0.30b 
8.08  
± 1.01ab 
Sp
ec
ifi
c a
cti
vi
-
ty
, A
U
/m
g o
f 
pr
ot
ein
 
proMMP9 14.04 ± 0.99b 
17.78 ±  
0.86b 
1.50 ± 
0.48a 
42.45  
± 1.87c 
proMMP2 13.82 ± 0.83ab 
17.55 ± 
0.79b 
8.38 ± 
0.29a 
40.72  
± 1.21c 
MMP2 13.45 ± 0.96b 
13.65 ± 
0.89b 
7.29 ± 
0.37a 
56.56  
± 1.63c 
Note: see Table 1.  
As can be seen from the presented data, this method let us deter-
mine the proenzymatic forms of MMP2 and MMP9, as well as mature 
MMP2 in the heart. Active MMP9 was not determined on the zymo-
grams under the conditions of our experiment (Fig. 7).  
According to our results, the gelatinolytic activity of the investigated 
MMPs in the hearts of the control group was 13.45–14.04 AU/mg of 
protein. Their activity increased in the rats of the DCMP-group, especially 
significant changes occurred for proMMP2 and proMMP9. Corvitin 
caused significant inhibition of all forms of investigated MMPs in frac-
tions of soluble cardiac proteins. Particularly pronounced changes were 
experienced by proMMP9, whose activity reduced 10-fold compared 
with the DCMP-group of rats. Less significant changes were found in 
activity of latent and mature MMP2, their activity decreased 2.1 and 1.9-
fold relative to the DCMP-group. The opposite effect was shown by al-
pha-ketoglutarate: the activity of the investigated MMPs was increased 
2.3–4.1 fold in rats of this group in comparison with the DCMP-group.  
 
Discussion  
 
Cardiotoxicity of doxorubicin, which is currently used to treat many 
malignant tumours, including the various forms of leukemia, lympho-
ma, melanoma, uterine carcinomas, breast, and gastric cancers has been 
intensively discussed in recent years. Several mechanisms may play a 
role in the effects induced by this drug, including mitochondrial dys-
function, increased production of ROS, oxidative stress, DNA damage 
and apoptosis (Nebigil & Desaubry, 2018). According to the ESMO 
Clinical Practice Guidelines, the consequences of doxorubicin adminis-
tration in humans can be acute (occurring during or immediately after 
treatment), early (occurring within one year of exposure), and late (occur-
ring one or more years after initial exposure) (Curigliano et al., 2012). 
Some strategies to prevent the cardiac toxicity of doxorubicin involve 
reducing dosages and prolonging the doxorubicin infusion time to limit 
its serum concentrations.  
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Fig. 4. Cytoplasmic expression of MMP2 in atrium and ventricle of control group (a, b), group with doxorubicin-induced cardiomyopathy (c, d),  
after administration of corvitin (e, f) and alpha-ketoglutarate (g, h); immunohistochemical method with Mayer’s hematoxylin; scale bar: 5 μm  
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Fig. 5. Cytoplasmic expression of MMP9 in atrium and ventricle of experimental group of rats: see Fig. 4.  
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In our animal model, we used repeated administration of lower do-
ses of doxorubicin for four weeks, and we investigated the effects of 
corvitin and alpha-ketoglutarate on the physiological, morphological 
and histopathological parameters of the heart. Special attention was paid 
to the study of expression and activity of matrix metalloproteinases 
MMP2 and MMP9, which take a part in cardiac remodeling.  
We have demonstrated that the repeated injections of doxorubicin 
(cumulative dose 10 mg/kg or 75 mg/m2) induced metabolic disorders, 
which led not only to the decrease of body weight but to significant 
changes of indexes of the heart weight and heart shape, as well as to 
histopathological changes in myocardium tissue of the experimental rats. 
According to the literature, the index of heart weight was almost un-
changed after the introduction of doxorubicin at the dose of 15 mg/kg 
for 8 weeks (Kamel et al., 2017), while in our experiment this indicator 
decreased 1.3 times in comparison with the control group, despite the 
use of a 1.5 times lower cumulative dose of this drug. In addition, we 
have determined a tendency to change in heart shape from ellipsoidal to 
globular and decrease CT : MT. These findings are in consistent with 
studies showing that oxidative stress contributes to the 1.4 times de-
crease of heart weight index, change of heart geometry and develop-
ment of its fibrosis (Angsutararux et al., 2015; Wang et al., 2019). Our 
histological findings indicate that the high risk of fibrosis under the in-
fluence of doxorubicin is caused by destructive-dystrophic changes in 
the left atrium and ventricle. This is supported by the fact that doxorubi-
cin cardiotoxicity is manifested not only by structural disorders of cardi-
omyocytes but also by functional changes in cardiac fibroblasts. This 
antibiotic promotes cellular aging and induces differentiation of cardiac 
fibroblasts into the pro-fibrotic phenotype, myofibroblasts (Cappetta 
et al., 2016). In addition, doxorubicin-mediated interstitial and perivas-
cular fibrosis occurs as a consequence of necrotic, apoptotic cell damage 
or pathological response to excessive ROS production (Carvalho et al., 
2013, Zhan et al., 2016).  
  
Fig. 6. Mixed cytoplasmic and intranuclear expression of MMP9  
in the heart of a rat with doxorubicin-induced cardiomyopathy  
(dot-like phenomenon indicated by arrows): immunohistochemical 
method with Mayer’s hematoxylin; scale bar: 5 μm  
  
Fig. 7. Zymograms that illustrated the proteolytic bands of gelatinases: 
proMMP9 (92 kDa), proMMP2 (72 kDa), and active MMP2 (64 kDa); 
DCMP – doxorubicin-induced cardiomyopathy,  
AKG – alpha-ketoglutarate  
Recent reports also indicated the key role of proteolytic enzymes in 
heart remodeling after doxorubicin treatment, especially matrix metallo-
proteinases, among them gelatinases A and B, or MMP2 and MMP9 
are the most frequently discussed (Munch et al., 2016; Meschiari et al., 
2017). These enzymes demonstrate substrate affinity for denatured col-
lagen, basement membrane proteins such as collagen type IV, fibronec-
tin, and laminin. MMP2 and MMP9 also exhibit proteolytic activity 
against elastin and proteoglycans. It was shown that the level of circula-
ting gelatinases can serve as indicators of dilated cardiomyopathy (Pyt-
liak et al., 2017), heart failure under doxorubicin treatment (Ivanova 
et al., 2012, Gordiienko et al., 2014), poor output of acute coronary 
syndrome (Lindsey et al., 2016) and efficiency of the therapy provided 
to heart failure patients (Radosinska et al., 2017). At the same time, the 
changes in expression and intracellular localization of these enzymes in 
heart tissue are poorly understood and discussed mostly as markers of 
post-infarction complications (Mayer et al., 2018). The results of our 
study indicate a profound cell damage, which is manifested by an in-
crease in the cytoplasmic expression of MMP2 and MMP9 in most 
atrial and ventricular cardiomyocytes, an unspecific intranuclear dot-like 
reaction, and increase of the MMP2/9 activity in the fraction of cardiac 
proteins. The findings are consistent with the results of other research-
ers,who found an increased expression of both gelatinases in the left 
ventricle of rats with cyclophosphamide-induced cardiomyopathy (Kol-
dysheva et al., 2018). This effect may be explained by the property of 
doxorubicin to cause oxidative stress through the activation of 
NAD(P)H-oxidase and inducible NO-synthase. That results in the gene-
ration of a large number of ROS, followed by activation of redox-sensi-
tive transcription factors NF-kβ/AP-1 and signaling cascades through 
G-protein, Ras and MAPK, as well as the release of a large number of 
proinflammatory cytokines and growth factors that synergistically stimu-
late overexpression of MMP2/9 (Octavia et al., 2012; Nakonato et al., 2015; 
Jung, et al., 2018). As was noted in our and other researches (Sinha et al., 
2014), a certain amount of MMP2/9 has intranuclear localization. Some 
authors thought that these enzymes may be able to be involved in nucleus 
remodeling processes by degradation of some nuclear proteins such as 
transcription factors and RNA processing proteins (Lin et al., 2014).  
At present, there are no specific clinical practice guidelines for the 
management of doxorubicin-induced cardiomyopathy. Overall, available 
cardioprotective measures include a combination of natural antioxi-
dants, beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, 
angiotensin receptor blockers, diuretics, nitrates, and hydralazine (Wang 
et al., 2019; Wenningmann et al., 2019). Among those, antioxidants, 
ACE-inhibitors and beta-blockers showed the best cardioprotective 
results in patients under doxorubicin treatment (Curigliano et al., 2012; 
Kamel et al., 2017). However, additional clinical studies are necessary 
to develop alternative pharmacological approaches and clinical practices 
for the diversified patient population treated with anthracycline based 
chemotherapy. Taking into consideration the fact that oxidative stress 
and proteolysis play a significant role in development of doxorubicin 
cardiomyopathy, we have investigated the cardioprotective properties of 
corvitin and alpha-ketoglutarate, which exhibit a powerful antioxidant 
effect (Tkachenko et al., 2018). As follows from the presented results, 
both drugs have an insufficient regenerative effect on the morphological 
parameters of the heart – heart mass index and heart shape index (Fig. 2a, b), 
but show a strong effect on the expression and activity of MMP and 
MMP9 (Fig. 5, 6, Table 2). The decrease of gelatinases expression in 
the atria and ventricle, suppression of their activity in the heart muscle 
under the influence of corvitin may be explained from the standpoint of 
its antioxidant properties. The hydroxyl residues in the structure of the 
bioflavonoid quercetin, which is a main constituent of corvitin, may be 
a donor of hydrogen for free radicals, forming flavonoxyl radical. Such 
effect may determine quercetin’s ability to restore superoxide dismutase 
activity, block NAD(P)H-oxidase, and enhance the synthesis of a tissue 
inhibitor of matrix metalloproteinases TIMP1, which impedes the acti-
vation of these MMPs (Wang et al., 2014). In addition, quercetin inhi-
bits the synthesis of gene expression factor NF-κB, which leads to de-
crease in tumour necrosis factor TNFα and, indirectly, to decrease in 
gelatinases expression (Dong et al., 2014). Besides, quercetin is able to 
block PKC/ERK/AP1, MAP kinase and cJNK/AP signaling pathways, 
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which also interfere with the expression of MMP2/9 (Wang et al., 2014). 
Unlike corvitin, the activity of the investigated MMPs is significantly 
increased with the simultaneous administration of doxorubicin and 
alpha-ketoglutarate. Probably, this effect is due not only to enhancement 
of the energy supply of myocardial cells, but also to the peculiarities of 
the composition of alpha-ketoglutarate. In our experiment we used the 
drug that contains the calcium and sodium salts of alpha-ketoglutarate. 
It is known that calcium ions are potent activators of matrix metallopro-
teinases both in vivo and in vitro. That is why Ca2+ is a necessary part of 
the incubation buffer during gelatin-zymography. Possibly, the pro-
longed administration of the calcium salt of alpha-ketoglutarate led to an 
increase in the activity of gelatinases.  
 
Conclusion  
 
The results of the study complement current views on the mechan-
isms of cardiotoxicity of the anthracycline antibiotic doxorubicin and 
provide new information about the cardioprotective effects of corvitin 
and alpha-ketoglutarate. The findings indicate that changes in MMP ac-
tivity and expression occur with the action of even low doses of doxoru-
bicin for 4 weeks. These changes are associated with impaired cardi-
omyocyte function, partial remodeling and fibrosis of the myocardial 
tissues. Antioxidants corvitin and alpha-ketoglutarate exert potent cardi-
oprotective effects, regulating the expression and activity of matrix 
metalloproteinases MMP2 and MMP9.  
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